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Abstract
Despite substantial efforts to understand the interactions between nanoparticles and cells, the
cellular processes that determine the efficiency of intracellular drug delivery remain largely
unclear. Here we examined cellular uptake of siRNA delivered in lipid nanoparticles (LNPs) using
cellular trafficking probes in combination with automated high-throughput confocal microscopy as
well as defined perturbations of cellular pathways paired with systems biology approaches to
uncover protein-protein and protein-small molecule interactions. We show that multiple cell
signaling effectors are required for initial cellular entry of LNPs through macropinocytosis,
including proton pumps, mTOR, and cathepsins. SiRNA delivery is substantially reduced as
≅70% of the internalized siRNA undergoes exocytosis through egress of LNPs from late
endosomes/lysosomes. Niemann Pick type C1 (NPC1) is shown to be an important regulator of the
major recycling pathways of LNP-delivered siRNAs. NPC1-deficient cells show enhanced cellular
retention of LNPs inside late endosomes/lysosomes and increased gene silencing of the target
gene. Our data suggests that siRNA delivery efficiency might be improved by designing delivery
vehicles that can escape the recycling pathways.
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tSmall interfering RNAs (siRNA) are a potential new class of medicines that can selectively
silence disease-causing genes1–3. LNPs are the most advanced siRNA delivery system to
date, having recently shown therapeutic efficacy in clinical trials4. Although efforts to define
the physicochemical properties of nanoparticles that contribute to efficient cellular delivery
are ongoing, the cellular factors that regulate nanoparticle-mediated siRNA delivery remain
largely unclear5–7.
Nanoparticles utilize different endocytosis pathways for cellular entry5. Intracellular
trafficking of nanoparticles is a dynamic process, which results in transport of
macromolecules to different subcellular destinations, with the majority of material targeted
to the lysosomes for degradation5. It has been hypothesized that the buffering capacity of
nanoparticles can activate the proton pump that accentuates osmotic pressure inside an
endosome, resulting in its swelling and subsequent endosomal escape of siRNA7,8.
Alternatively, it has been suggested that cationic lipids in LNPs can interact with anionic
lipids of the endosome, causing destabilization of the endosomal membrane9. Regardless of
the release mechanism, imaging studies have shown that nucleic acids are largely trapped
inside the endo- and lysosomes with only a small fraction being released to the
cytoplasm10–12. Endosomal transport requires multiple heterotypic or homotypic endocytic
fusion events with constantly changing vesicular milieu regulated by a diverse set of
endosomal proteins and different cell signaling cascades13,14. The effect of this interplay
between cell signaling and endocytosis on LNP trafficking needs to be further defined.
In this study, we utilized an automated, high-resolution microscopy-based screening
approach with a library of small molecules that have a range of effects on cell signaling,
endocytosis and autophagy to identify key regulators that are important for cellular uptake of
cationic LNPs that can encapsulate siRNA (Supplemental Information-Small molecule
library). These LNPs were formed by the complexation of siRNA with the cationic lipid,
C12-200 and were further formulated with different excipients using a previously reported
microfluidic process that generates slightly positively charged nanoparticles (ca. 70-80 nm
in size)15; they have demonstrated unprecedented efficacy in the delivery of siRNA in
vivo16,17. The potency of this delivery system tested in rodents and non-human primates is
at a range similar to LNPs at the forefront of clinical trials4. In rodents no liver toxicity was
observed at 1 mg/kg, a dose hundred fold above the efficacious range of silencing.16
When HeLa-GFP cells were incubated with LNPs containing Alexa-647-labelled siRNA
against GFP for 3 hrs, the particles appear to localize at the perinuclear region within 1 hour
post exposure (Fig S1 a-b). Subcellular localization of LNP-siRNA in the presence of small
molecule inhibitors under similar conditions was visualized and the amount of internalized
siRNA was quantified. The small molecule library consisted of molecules that affect cell
signaling, intracellular trafficking as well as had the ability to either induce or inhibit
autophagy (for a list of the inhibitors used and the quantification of their effect on LNP
uptake see Supplemental Information Small Molecule Library). We considered the subset of
small molecules that had substantial inhibition on LNP uptake and using databases (See
Supplementary Information Methods) identified the proteins with which the small molecules
interact with and created protein-protein and protein-small molecule interaction networks.
This systems analysis identified several endocytic regulators required for LNP entry which
includes VoATPase, mTOR (mammalian target of rapamycin), cathepsins, Protein Kinase C,
NFκ B, calcium channels, chloride channels and arachidonic acid metabolic pathways (Fig
1a). Previous work has identified, among other processes, signaling cascades such as mTOR
and cathepsins, as regulators of the cellular uptake of glucose and viruses by
macropinocytosis18,19. We have summarized known effectors of cellular trafficking in Table
S1. Because previous studies show that interference with acidification impacts release of
nucleic acids from endosomal compartments20, our results further corroborated the effects of
Sahay et al. Page 2
Nat Biotechnol. Author manuscript; available in PMC 2014 January 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tproton pump on endocytosis of LNPs. We found that the VoATPase inhibitor, bafilomycin
inhibits LNP entry inside cells (Fig 1b) whereas having no effect on the LNPs stability
(FigS2a). Multiple LNPs with different cationic lipid compositions containing siRNA or
Hydrogenated soybean phosphatidylcholine (HSPC)-based liposomes containing small
molecules showed marked decrease in uptake in the presence of two different proton pump
inhibitors, concanamycin and bafilomycin (FigS2b-c)21 . Furthermore, treatment with
bafilomycin led to a decrease in siRNA-induced target gene silencing (Fig 1c).
We further investigated the interactions of the LNPs with the cell membrane in the presence
or absence of bafilomycin using time lapse total internal reflection fluorescence microscopy
(TIRFM) that allows for high resolution imaging at the cell surface. Multiple particle
tracking revealed that LNP-positive vesicles moved on average six times faster in untreated
cells than in bafilomycin-treated cells. After bafilomycin treatment endosomes also appear
to form in substantially lower numbers (3-fold less) and had a slower rate of disappearance
(increased track duration) from the focal plane (Fig 1d-e and Movies S1-S2). Two-fold
fewer LNP positive vesicles were observed after bafilomycin treatment and those that form
get enlarged due to a block in transport of early endosomes to late endosome/lysosomes (as
has been previously reported22).
To identify internalization pathways that are required for cationic LNP entry into cells we
depleted key endocytic regulators using siRNA in HeLa cells. Down-regulation of Cdc42
and Rac1 (regulators of macropinocytosis) led to ca. 80% decrease in LNP uptake whereas
inhibition of clathrin heavy chain-1 and caveolin-1 (regulators of clathrin and caveolae
mediate endocytosis, respectively) had little impact on LNP entry (Fig 2a). Further transport
of LNPs to select endocytic compartments in these cells was analyzed through co-
localization studies based on endocytic markers. First, LNP initial entry through
macropinocytosis was confirmed through strong localization with Cdc42-GFP and
ovalbumin positive vesicles (both markers for macropinocytosis) as compared to that with
Arf6-GFP positive vesicles (clathrin-and dynamin-independent pathways) (Fig S3a).
Second, image based kinetics of LNP delivery to the general endo/lysosomal system
revealed little co-localization of LNPs with EEA-1 or Rab5-RFP (early endosome markers)
(post 3 hr incubation, at multiple time chase points, ca. 5-10% co-localization) but a steady
increase in co-localization with LAMP-1, LAMP-2, Rab7-GFP and Lysotracker positive
vesicles (late endosome/lysosome marker) starting as early as after 15 min chase and
showing a steady increase to around 50% localization with late endosomes/lysosomes after
60 min (Fig 2b-c, Fig S3b-c). Notably, after 60 min a fraction of the labeled siRNA starts to
show co-localization with markers of the tubulovesicular endocytic recycling compartment
(ERC) (Rab11-GFP, antibody against Rab-11, transferrin) whereas a decrease in localization
with lysosomal positive vesicles was observed (Fig 2b-c, Fig S3c). Inhibition of Rab11
(Rab11 siRNA and dominant negative (DN)-Rab11) to interfere with early endocytic
recycling causes a 1.5 fold reduction in LNP internalization (Fig S3d-e). This decreased
internalization may be a result of reduced endocytic recycling of trafficking regulators
required for LNP entry.
Autophagy, another catabolic process which routes cytosolic proteins to the lysosomes23,24,
was apparently not involved in LNP-mediated gene silencing as LNPs showed little co-
localization with markers of autophagy (Fig S4a-b). Autophagy deficient cells (Atg5−/−)24
showed little if any differences in LNP mediated gene silencing when compared to
autophagy competent (Atg5+/+) cells (Fig S4c).
Overall, C12-200-based cationic LNPs utilize macropinocytosis to enter cells and bypass the
early endosomes; a small fraction is directed to the ERC while most LNPs traffic towards
the late endosome from where they are routed to the lysosomes. Our results are consistent
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twith previous studies that cationic LNPs utilize distinct mechanisms of entry when
compared to ionizable LNPs, which internalize through ApoE dependent entry
mechanisms16,25.
In addition to the moderate co-localization of LNPs with ERC, our imaging studies also
indicated a considerable redistribution of LNPs in the presence of wide variety of
compounds from the screen that cause stress on the endoplasmic reticulum. (Supplemental
Information Small Molecule Library). Therefore, we wanted to quantify the kinetics of LNP
disassembly and the relative contributions of internalization and recycling on siRNA
delivery using a FRET probe26. The probe contains two identical siRNA’s, each labelled
with a different fluorophore that together form a FRET pair. The siRNA-bound fluorophores
aggregate with the cationic lipids in the nanoparticle mixture and undergo FRET, which is
indicative of intact LNPs. Flow cytometery data shows a time dependent decrease in FRET
based fluorescence signal within 1 hour of internalization, which was indicative of LNP
disassembly inside cells (Fig 3a). However, the fluorescence emanating from a single
fluorophore (AF647) remained constant during this time. A decline in AF647 signal was
observed only after 1-4 hrs which substantially diminished after 24 hrs. Therefore, LNPs
disassemble rapidly within the first hour of entry followed by degradation or recycling of
siRNA within 24 hrs (Fig 3a). Labelled siRNA was located in vesicular compartments
alongside microtubules 1 hour post incubation; indicating that, most siRNA’s remain
trapped inside endosomes after nanoparticle disassembly (Fig 3b).
To show that the reduction of intracellular siRNA-linked fluorescence was due to recycling
of the siRNA to the extracellular media, we measured the fluorescence in the supernatant at
multiple time points post transfection. We found an increase in the fluorescence intensity
that appeared within 6 hrs post incubation and reached saturation at 24 hrs in the
extracellular milieu (Fig 3c). Because intact nanoparticles partially quench fluorescence
from the siRNA encapsulated inside them, we exposed the supernatant to Triton-X to
dissociate any intact LNPs. Exposure to Triton-X resulted in little changes in fluorescence.
This suggested that most LNPs had, in fact, disassembled inside cells, confirming our FRET
based data. Approximately 36% of the initial amount of siRNA incubated with the cells
recycled into the supernatant and 2.5 times (70%) the amount of the stable siRNA was
present in the supernatant relative to inside cells after 24 hrs (Fig 3d, Fig S5).
Subcellular trafficking of lipids (e.g. cholesterol) from late endosomes/lysosomes towards
the extracellular milieu has been reported to utilize the thirteen transmembrane glycoprotein
NPC1 which is located on the surface of multivesicular late endosomes. Absence of NPC1
causes late endo/lysosomal dysfunction, cholesterol accumulation and is implicated in a
lysosomal storage disease that causes liver and neural degeneration in human patients and
animal models27–29. As the components of an LNP show some similarities to the
endogenous lipids that use NPC1 as a receptor for recycling, we compared LNP retention in
mouse embryonic fibroblasts (MEFs) devoid of NPC1 (NPC1−/−) with their wild type
counterparts (NPC1+/+ MEFs) (Fig 4a). NPC1 deficient cells accumulate cholesterol due to
defects in recycling (Fig S6). A markedly increased level (approximately 15 fold) of AF647-
siRNA was observed in perinuclear enlarged endosomes in NPC1−/− compared to NPC1+/+
MEFs at 24 hrs post incubation, presumably due to enhanced cellular retention at a wide
range of LNP concentrations (Fig 4a-b). Furthermore, enhanced cellular retention was
observed in multiple cell types deficient in NPC1 including those isolated from human
patients (FigS7a-b). We further tested for differences in the kinetics of LNP uptake in these
cells. NPC1−/− cells show increased accumulation of siRNA after 2 hour of incubation as
compared to NPC1+/+ cells where at early time points the amount of internalization is not
effected. Moreover, a rescue experiment where we transfected an NPC1-GFP plasmid into
NPC1−/− cells reduced the amount of intracellular LNP-siRNA to that of wild type cells (4c
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t(i-ii)). We conclude that the increased level of siRNA in late endosomes is based on
accumulation of LNPs due to defects in constitutively active NPC1 mediated recycling.
Small molecules that impair cholesterol metabolism28 and increase cholesterol accumulation
in cells failed to yield a significant increase in LNP accumulation (Fig S7c). Thus, the
increased accumulation of LNPs is not due to just increased endosomal cholesterol but
rather due to lack of direct interaction with putative intraluminal domains of NPC1 required
for egress of LNPs. NPC1−/− cells have been reported to have high numbers of enlarged late
endosomes, containing intraluminal vesicles enriched in lysobisphosphatidic acid (LBPA)29.
LNPs accumulate in these structures and showed co-localization with antibody against
LBPA in these cells (Fig 4d).
To study the broader potential relationship between lipid structure and NPC1-dependent
LNP retention, we tested cationic siAF647-LNPs formulated with a small set of lipidoids
consisting of two different amine cores, each with lipid tails of increasing chain lengths (Fig
S-Reaction Scheme). Different LNPs containing related cationic lipids also showed
increased retention in NPC1-deficient cells. We also found that increased carbon chain
lengths of these cationic lipids led to better uptake and retention in both NPC1+/+ and
NPC1 −/− MEFs (Fig S8a-b). This marked retention is consistent with studies that show that
lipids with higher chain length can insert inside NPC1 carrying late endosome membranes30.
Notably, liposomes containing small molecules showed similar increases in cellular
retention in knock out cells (Fig S8c).
To determine whether the absence of NPC1 also leads to increased retention with polymeric
nanoparticles, we tested polystyrene nanoparticles of different sizes and charges. We found
a moderate increase in retention and perinuclear distribution with positively and negatively
charged particles at sizes of 100 or 200 nm in NPC1 −/− cells whereas negatively charged
particles 20 nm in size (known to use caveolae mediated pathway31) showed similar
retention when compared to wild type cells (Fig S8d). We found that dextran, a marker for
macropinocytosis, shows increased retention in KO cells as compared to markers of
caveolae or clathrin-dependent endocytosis (data not shown). Thus, 20 nm particles that can
access 80 nm caveolae5,31 due their smaller size are able to be retained inside both cell types
(NPC1 −/− and NPC1 +/+) when compared to larger particles that may only utilize
macropinocytosis to gain entry. It is possible that macropinosomes directly fuse with NPC1
positive late endosomes and are recycled to the extracellular milieu, in the absence of which
the cargo remains diverted to the endolysosomal system. It is believed that in the case of
certain types of cargo, NPC1 independent recycling allows for partial escape from the endo-
lysosomal system30. This may not be the case with longer chain lipids that require
interaction with NPC1 for cellular exit30. This may be the reason for the major retention of
LNPs as compared to polystyrene nanoparticles.
We hypothesized that enhanced cellular retention could translate to improved gene
silencing. LNPs containing β -integrin siRNA were added to either NPC1+/+ or NPC1−/−
MEFs at different concentrations. A substantial improvement in LNP potency was observed
in NPC1−/− cells in comparison to wild type cells (Fig 4e). The IC50 of 1.5 nM in NPC1
deficient cells was roughly 10 times lower than in wild type MEFs, and the improved
potency was seen across all LNP doses tested (Fig 4e). To further measure cellular retention
and siRNA efficacy, NPC1+/+ and NPC1−/− MEFs (stably transfected with GFP) were
treated with LNPs containing GFP siRNA (siAF647-GFP); high-throughput microscopy was
used to simultaneously measure cellular retention and GFP fluorescence 72 hrs post
incubation in both cell types. Enhanced cellular retention of siAF647-GFP and a decrease in
normalized GFP fluorescence in NPC1 −/− compared to that in NPC1+/+ cells were observed
confirming our previous results (Fig S9a-c). Next, we utilized siRNA against NPC1 to
experimentally lower NPC1 protein levels in wild type cells and a 60% reduction in protein
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tlevel was achieved (Fig S9d-e). A 4-fold increase in LNP efficacy was observed in wild type
cells treated with NPC1 siRNA when compared to the luciferase control (Fig S9f). Although
this LNP efficacy is lower than what is achieved in NPC1−/− cells, 40% NPC1 protein still
remains in NPC1+/+ cells treated with siNPC1 and this amount may still sufficient to recycle
some LNPs, albeit at a less efficient rate. The use of lipids for transfection of NPC1 siRNA
may alter intracellular trafficking or recycling and further explain why these effects were
partial with siRNA knockdown versus the effect seen in complete NPC1−/− MEFs.
This led us to further investigate which endocytic recycling pathways participate in
exocytosis of LNPs, and in particular whether inhibition of these pathways could enhance
cellular retention and LNP mediated gene silencing. Late endosomes have been shown to
exchange material with the Golgi/ER from where the cargo can be secreted to the
extracellular milieu32,33 and/or multivesicular bodies that can fuse with the plasma
membrane to release their intracellular content as exosomes34. Therefore, we examined the
effects of siRNA that blocks secretion from the Golgi/ER (Rab8a)32 or exosomes secretion
and/or fusion with the plasma membrane (Rab27a and Rab27b)34. Rab8a and Rab27b
siRNA treatment led to significant increase in retention of LNP in cells. A moderate increase
in LNP retention was observed after reduction of Rab27a expression (Fig S10 a-f). Notably,
only in the case of Rab27b depletion did we detect a substantial improvement in LNP
mediated gene silencing (Fig S10 g). Recent reports have shown that Rab27b inhibition
leads to redistribution late endosomes in the perinuclear region34. Concurrently, in our
experiments both Rab27b-depleted and NPC1-deficient cells show similarly increased
perinuclear retention of LNPs which contains functional siRNA that contributes to enhanced
gene silencing. On the other hand siRNA against Rab11 did not improve retention and gene
silencing (Fig S10 h-i), these results are consistent with previous reports that NPC1-
mediated recycling of endogenous lipids is independent of Rab11 function even though they
show some co-localization with Rab11 positive ERC35.
In summary, to enter cells, cationic LNPs require Cdc42 dependent macropinocytosis which
is shown to be regulated through VoATPase, once internalized remain largely trapped within
endosomes with little escape to the cytosol. LNP-mediated siRNA delivery can be impaired
by either lack of LNP disassembly inside endosomes or their subsequent degradation in the
lysosomes as well as recycling from the cell. In the absence of NPC1, due to decrease in
motility of late endosomes29, LNPs remain in enlarged late endosomes/lysosomes and are
not recycled back out of the cell. One hypothesis to explain how this leads to a greater
efficiency in siRNA-mediated gene silencing is that the increased residence time of more
siRNA inside cells results in a slow controlled diffusion of the siRNA into the cytoplasm
(Fig 4f (i-ii)). It appears that late endosome/multivesicular late endosomes may serve as a
transient reservoir where LNP recycle through multiple pathways. Prevention of LNPs direct
egress from the late endosomes leads to enhanced retention and perinuclear positioning of
these vesicular structures may serve as a persistent site for endosomal escape. Future studies
that target proteins and lipids involved in biogenesis, trafficking and recycling of the late
endosomes may provide further clues into the cellular factors that may improve drug
delivery. Finally, the RNA-induced silencing complex (RISC) has been shown to be
associated with membranes of late endosomes, and certain RISC complex components can
be seen inside intraluminal vesicles of late endosomes/exosomes as well as the cytosolic side
of the perinuclear rough endoplasmic reticulum 36–39. It is possible that, in NPC1 deficient
as well as Rab27b depleted cells, LNPs remain stalled in a manner that affects siRNA
delivery to RISC. From a therapeutics perspective, it is tempting to speculate that LNPs may
demonstrate enhanced siRNA/drug delivery in lysosomal storage diseases where NPC1
function is impaired.
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tFigure 1. Systems survey for endocytosis of lipid nanoparticles (LNP)
LNPs containing siAF647 were incubated with HeLa-GFP cells (50nM) for 3 hrs in the
presence or absence of small molecules and imaged using an automated high throughput
confocal microscope a. Small molecules that inhibit over 80% of internalization (with no
more than 10%-15% loss of cell viability) and their network interactions are presented in the
form of a systems diagram b. Localization of siAF647LNP in presence or absence of
bafilomycin is represented as an individual image (arrows indicate peripheral localization)
and a 3D z-stack. c. Dual HeLa cells were exposed to LNP (siLuc, 10nM) in the presence or
absence of bafilomycin (1μ M). Luciferase to Renilla levels was measured for silencing
activity. Experiments were performed in triplicate; errors are plotted as standard error means
(S.E.M.). (d-e). Time lapse Total internal reflection (TIRF) microscopy of cells exposed to
siAF647-LNPs (50nM, 3hrs) in the presence or absence of bafilomycin was subjected to
multiple particle tracking (MPT). A snapshot of vesicular tracks indicating the movement of
LNPs in presence or absence of bafilomycin presented in (d). The ratio between the MPT
parameters for untreated/bafilomycin treated cells was calculated to provide a quantitative
measure of differences in LNP trafficking with or without bafilomycin (e). Errors of ratios
are plotted through propagation of errors from division.
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tFigure 2. Cellular trafficking of LNPs
a. Quantitative image analysis of siAF647-LNP cellular uptake (3 hrs) in HeLa cells
silenced with siRNA against key endocytic regulators (Cdc42, Rac-1, Clathrin heavy chain
(CHC), caveolin-1 (Cav-1). siRNA against luciferase serve as a negative control. (b-c)
Image based quantitative analysis of siAF647-LNPs co-localization (3 hrs pulse, 15, 30, 60
min. chase) with markers of endocytosis, anti-EEA-1 (early endosomes), anti-LAMP-1 (late
endosome/lysosomes), anti-LAMP-2 (late endosomes/lysosomes), Rab11-GFP and anti-
Rab11 (both mark endocytic recycling compartment). High-resolution z-stack confocal
images representative of 60 min chase are presented in different panels (b). Quantification of
LNP-siRNA cellular uptake after indicated times (a, c).
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tFigure 3. Quantitative analysis for disassembly and recycling of LNPs
a. HeLa cells were exposed to LNP with the FRET pair (AF647/AF594 siRNA), washed and
replenished with media. Changes in FRET (excitation-561 nm, emission-641 nm) intensity
were monitored at different time points using flow cytometery to quantify LNP disassembly.
The emission from a single fluorophore (excitation-633 nm, emission-641 nm) was used to
measure intracellular siRNA at these time points. b. Cellular uptake of FRET probe-LNP
(siAF647/siAF594, 3hrs) was imaged in stably transfected GFP-tubulin cells 1 hour post
incubation c. siAF647-LNP was pulsed for 3 hrs, washed and incubated with fresh media to
remove non internalized particles. Media was removed at multiple time points and analyzed
using a fluorescent reader to determine amount recycled. 1% Triton-X was later added (red
curve) to the media and fluorescence was re-measured. d. Amount of siRNA was obtained
from fluorescence values from (c) that were extrapolated using the standard curve (inset).
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tFigure 4. Enhanced cellular retention and efficacy of siAF647-LNPs in NPC1 deficient MEFs
a. Immunoblot analysis with anti-NPC1 antibody was used to validate wild type and NPC1
deficient MEFs. b. Automated confocal microscopy on NPC1+/+ or NPC1−/− MEFs exposed
to different concentrations of labeled LNPs and imaged 24 hrs post incubation. Inset from a
representative image (100 nM) shows siRNA accumulation in individual cells. c. Flow
cytometery analysis on LNP-siRNA uptake in (i) NPC1+/+ or NPC1−/− cells or in (ii)
NPC1−/− cells transfected with pEGFP or pNPC1-GFP. The mean fluorescent intensity
represents LNP uptake. d. NPC1−/− cells treated with LNP-AF647-siRNA (red) (3 hrs pulse,
30 min chase) and immuno-stained with anti-LBPA antibody (green) e. LNPs containing
siRNA against β  integrin were added to wild type or NPC1 deficient MEFs as in (a), mRNA
levels were quantitated at 24 hrs post incubation using branched DNA analysis. The
experiment was done in triplicate and the errors are reported as S.E.M. f. A schematic
representation of LNP trafficking (i) in NPC1+/+ and (ii) NPC1−/− cells. Intact cationic
LNPs enter through macropinocytosis (1); a small fraction of LNPs transport from
macropinosomes to the endocytic recycling compartment (ERC) (2) while the majority is
directed to late endosomes (3). Late endosome sort LNPs to lysosomes for degradation or
utilize multiple recycling pathways to traffic them to the extracellular milieu. These
mechanisms include recycling through transport to the ER-Golgi route (4) or direct fusion of
late endosomes containing multivesicular bodies, with the plasma membrane (Exosomes
secretion) (5). In NPC1 deficient cells the late endosome recycling mechanisms are impaired
causing LNP-siRNA to accumulate in enlarged late endosomes leading to persistent escape
of siRNA that improves gene silencing. (Intact nanoparticle- , siRNA complex- )
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